A double-blind, randomised, placebo-controlled trial to evaluate the effectiveness of late gestation oral melatonin supplementation in reducing induction of labour rates in nulliparous women. The MyTIME study protocol

Introduction Around the world, rates of induction of labour (IOL) amongst nulliparous mothers have increased in the last 10 years. In Australia, rates have increased over the last decade by 43%, from 32% to 46%. There is growing concern about the rapid rise in IOL before 41 weeks for nulliparous women without medical complications because of the associated increased rates of caesarean section, reduced satisfaction with birth, and birth trauma. Melatonin potentiates the action of oxytocin and may promote the spontaneous onset of labour; therefore, we will test the hypothesis that exogenous melatonin supplementation in late pregnancy will reduce the rate of labour induction by 30% or more.

Methods and analyses This is a double-blind, randomised, placebo-controlled trial in nulliparous pregnant women to reduce IOL rates. We will randomise 530 women to receive either 3 mg oral melatonin or placebo daily from 39⁺⁰ weeks gestation until they give birth. The primary endpoint will be IOL rate after 39 weeks. Secondary endpoints will include: interval between administration of trial medication and birth; a range of maternal and neonatal outcomes, including birth outcomes; breastfeeding on discharge, at 10 days and at 2 months; maternal satisfaction; child developmental outcomes at 2 months of age; and cost-effectiveness of melatonin compared with standard care. All data will be analysed by intention to treat.

Ethics and dissemination The study is approved by the Women and Newborn Health Service (WNHS) Human Research Ethics Committee (HREC) (RGS0000006283).

Trial findings will be disseminated through conference presentations and peer reviewed publications.

Trial registration number The trial has been prospectively registered on the Australian New Zealand Clinical Trials Registry as ACTRN12623000502639

• This is the first registered randomised placebo-controlled clinical trial investigating the effect of melatonin to improve the onset of spontaneous labour from 39 weeks gestation and therefore, reduce the rates of women requiring IOL. Both participants and clinicians will be blinded to intervention allocation, ensuring decisions regarding induction of labour cannot be influenced by the allocation.

• Exploration of child developmental outcomes is a strength, not previously undertaken in trials including melatonin supplementation in pregnancy.

• Sub study findings from participants with Gestational Diabetes Mellitus (GDM) will provide novel pilot data regarding the potential role for melatonin in blood glucose control.

• A limitation of our trial is that is conducted within one health service area which may limit generalisability; however, this area is large, encompassing 4 separate sites, various models of care and all capability levels of maternity care (primary through to quaternary) minimising the impact of this selection bias.

• Singular health service governance over such a large variety of settings supports protocol implementation and compliance, reducing variability and improving trial quality.